Medical microbiology Portfolio Pathway evidence must span all four curriculum pillars: laboratory diagnostics, clinical infection advice, infection prevention and control, and antimicrobial stewardship. The lab work is the easiest to document; the advisory and stewardship pillars require a structured, contemporaneous log approach. A portfolio strong in one or two pillars but thin on the others will attract a deferral request from RCPath assessors.
The four curriculum pillars and why balance matters
Most specialties ask you to demonstrate clinical competence in a reasonably unified domain. Medical microbiology asks you to demonstrate competence across four meaningfully different areas, each with its own evidence logic. The Medical Microbiology Portfolio Pathway complete guide explains the overall structure; this article focuses on the documentation challenge that trips up otherwise strong applications: capturing all four pillars with equal depth.
The four areas are defined in the GMC Specialty Specific Guidance (SSG) for Medical Microbiology, which draws on the RCPath Medical Microbiology curriculum. Before reading further, confirm you have the current version of the SSG from the GMC website. The SSG is the document RCPath assessors work from when evaluating your application, and the evidence you submit should map explicitly to the capabilities described there. The general principle is explained in more detail in the SSG guide.
The single most common error in medical microbiology Portfolio Pathway applications is treating the laboratory work as the primary evidence and treating the advisory pillars as supporting material. RCPath assessors look at all four pillars in detail, and an application that provides a thorough laboratory evidence section alongside thin or anecdotal coverage of AMS, IPC, or clinical advisory work will not pass. Think of each pillar as needing its own evidence file within your overall portfolio.
Laboratory diagnostics evidence
The laboratory pillar is the one most medical microbiologists feel confident about, because the evidence exists in the systems they work with every day. The task is extracting it, organising it, and presenting it in a form that assessors can evaluate quickly. A thorough bench-level description of how the laboratory operates is not what is being asked for here. The evidence should demonstrate your personal role as the consultant-level decision-maker in diagnostic interpretation, not the laboratory's processes.
What to extract from laboratory information systems
Your laboratory information system (LIS) is your primary source of authorisation data. Most NHS microbiology LIS platforms - including TELEPATH, ICE, and APEX - can generate personalised authorisation summary reports showing the volume and type of specimens you have authorised over a defined period. The report should show, at minimum: your total authorisations by specimen type over your log period; a breakdown by microorganism or test category (blood cultures, respiratory specimens, urine, wound swabs, serology, and molecular tests as appropriate); and, where the system records it, your turnaround time profile.
If your LIS cannot generate a named personal summary, your laboratory manager or quality lead should be able to extract the relevant data and provide a signed summary confirming your role and the data source. This is an acceptable alternative to a direct LIS export. What is not acceptable is a general description of the laboratory's workload without any confirmation of your personal contribution.
Specialist and molecular diagnostics are particularly worth drawing out separately. If you have authorised or contributed to interpretation of specialised tests - extended antimicrobial susceptibility panels, 16S rRNA gene sequencing reports, respiratory virus PCR panels, or diagnostic tests for unusual pathogens - document these explicitly. This type of work demonstrates diagnostic breadth beyond routine bacteriology and is rarely well-evidenced in applications that rely solely on aggregate specimen counts.
Blood culture result authorisation is worth tracking specifically, separate from the general LIS summary. Blood cultures sit at the interface of laboratory diagnostics and clinical advisory work: a bacteraemia result requires interpretation, patient identification, clinical context assessment, and timely communication with the clinical team. A blood culture authorisation log that shows not just the volume but the variety of organisms encountered, the communication actions taken, and any complex cases where clinical liaison was needed, evidences both Pillar 1 and Pillar 2 simultaneously.
EQA participation and external verification
External quality assurance participation provides independent, third-party verification of your diagnostic accuracy. UK NEQAS for Microbiology offers schemes covering bacteriology, mycology, parasitology, and mycobacteriology, amongst others. Your Trust's laboratory will be registered with relevant schemes and your personal performance data on distributed specimens - which will show how your identifications and susceptibility interpretations compared to the consensus answer - is the most objective quality marker you can include in a microbiology Portfolio Pathway application.
If you are not currently participating in EQA under your own identifier, enrol now. EQA results retrospectively attributed to the laboratory as a whole, rather than to you individually, carry less weight. The earlier you enrol, the more data you can accumulate before your application window opens. Details of the relevant schemes are available on the UK NEQAS website.
Clinical infection advisory work
The clinical advisory pillar is where the documentation challenge is most acute. Medical microbiology is not a specialty where patients are admitted under your name and where a clinical system automatically records your consultations. The advisory work happens in the form of phone calls, ward visits, infection MDT contributions, and formal clinical consultations - all of which disappear from the record unless you create one.
The correct approach is to maintain a structured advisory referral log, kept contemporaneously, throughout your log period. A log started retrospectively in the three months before you submit is much weaker than one maintained consistently over two or more years, because the latter demonstrates sustained practice rather than a pre-submission sprint.
Each log entry should capture: the date; the clinical setting (ward, GP, MDT, phone); the clinical question put to you; the advice you gave; any follow-up required; and a brief reflective sentence on what the case illustrates about your advisory practice. A log of 50 to 100 entries across your evidence period, even at this brief level of detail, is a substantial document that demonstrates sustained, senior advisory practice. Fifty entries is not an unrealistic target for a consultant-level microbiologist; in many NHS trusts with active infection teams, that represents perhaps six to eight weeks of normal work.
Case-based discussions and structured assessments
The advisory referral log provides volume evidence; structured assessments provide verified evidence. Case-based discussions (CbD) with a senior colleague or an infectious diseases consultant, focused on complex infection management cases, are the most credible form of independent verification for the clinical advisory pillar. A CbD that addresses your diagnostic reasoning, your communication with the clinical team, your antibiotic choice rationale, and your follow-up plan covers Pillar 1 and Pillar 2 evidence simultaneously.
Six to ten CbDs over your log period is a reasonable target. They should not all be on straightforward community-acquired pneumonia or uncomplicated urinary tract infection. Include cases with diagnostic complexity - a patient with a prior negative result who re-presents with a different organism, a bacteraemia where the source took time to identify, or a case where your advice changed the clinical course materially. The workplace-based assessments article covers the CbD tool in detail.
Infection MDT participation
Most NHS trusts with a microbiology department run some form of infection multidisciplinary meeting - variously called an infection MDT, a complex case meeting, a bone and joint infection team, or similar. Regular, documented attendance at such a meeting provides evidence of consultative clinical practice. The documentation requirements parallel those for any MDT role: attendance records confirming your participation, your role (presenting cases, advising on management, providing laboratory context), and reflective entries on specific cases where your contribution influenced clinical decisions.
The difference between MDT participation as evidence and MDT attendance as a job plan activity is reflection. A letter from your department confirming you attend the weekly infection meeting says you were there. A reflective entry describing a case where your identification of a rare organism changed the antibiotic choice, or where your interpretation of susceptibility data clarified an apparently conflicting result, says you contributed clinically. The former is a supporting document; the latter is portfolio evidence. The reflective practice writing guide sets out how to write reflections that pass assessor scrutiny.
Infection prevention and control
The infection prevention and control pillar requires evidence that you have played an active advisory role in your Trust's IPC function, not merely that an IPC team exists at your Trust. The two things are not the same, and assessors are alert to portfolios that conflate them.
The lead document for this pillar is usually a structured reference or letter from your Trust's Director of Infection Prevention and Control (DIPC), or an IPC lead who can speak to your specific contributions. This reference should confirm: the scope of your IPC advisory role (committee advisory contributions, individual outbreak advice, training delivery); specific incidents or outbreaks where you had a clearly defined role; any IPC committee or subgroup membership; and the frequency and nature of your interaction with the IPC team. A generic confirmation of employment is not the same as a structured reference addressing your IPC role.
Outbreak investigation evidence
Outbreak investigations are the highest-value IPC evidence you can generate, because they are complex, time-limited events that require all four curriculum pillars simultaneously: laboratory interpretation of outbreak strains, clinical advice on affected patients, IPC implementation of control measures, and often AMS input on empirical therapy during the outbreak. An outbreak investigation report in which you played a substantive role - as lead investigator or as the microbiologist advising the IPC team - is outstanding portfolio evidence.
The report should follow the standard outbreak investigation format: background, case definition, case-finding, epidemiological analysis, microbiological findings, control measures implemented, outcome, and lessons learned. Your portfolio should include either a copy of the formal outbreak report (redacted of patient identifiers) or a structured summary of your role, supported by a reference from the DIPC or outbreak team confirming your contribution. Root cause analysis (RCA) reports for significant healthcare-associated infection (HCAI) incidents follow a similar format and carry similar weight where a formal outbreak investigation was not triggered.
Many medical microbiologists work in trusts where the IPC nursing team handles most day-to-day IPC activity, with the microbiology consultant providing episodic advisory input rather than a sustained, formal IPC role. If this describes your situation, be honest about it in your portfolio narrative rather than attempting to inflate the extent of your IPC involvement. Assessors will be looking for credible evidence of your IPC role, not for you to present yourself as a full-time IPC consultant. What matters is that your contributions are real, documented, and mapped to the relevant curriculum capabilities.
Surveillance, reporting, and teaching
Healthcare-associated infection surveillance - MRSA bacteraemia, C. difficile infection, E. coli bacteraemia, and surgical site infection rates - is a routine output of the microbiology laboratory, and most microbiologists have some involvement in compiling or reviewing these data. For portfolio evidence, what matters is your advisory role: presenting surveillance data to the Trust board or IPC committee, contributing to the annual IPC report, or leading a surveillance-driven quality improvement project that resulted in a measurable change in HCAI rates. The quality improvement projects guide covers how to frame a surveillance-driven QI project for Portfolio Pathway evidence.
IPC teaching - infection link nurse training sessions, preceptorship teaching for foundation doctors on antimicrobial prescribing and hand hygiene, or formal IPC induction teaching - maps to the teaching evidence pillar as well as the IPC curriculum capability. A teaching session with clear learning objectives, an attendance record, and a brief reflection on its impact is a dual-purpose evidence item. The teaching evidence guide covers the framework.
Antimicrobial stewardship
Antimicrobial stewardship (AMS) is the fourth pillar and the one most likely to be treated as an afterthought in Portfolio Pathway applications. This is partly because AMS sits in a grey area between laboratory practice, clinical advisory work, and governance - it feels like it belongs to everyone and so gets claimed by no-one in particular. For your portfolio, it needs its own clearly delineated evidence stream.
The GMC SSG for Medical Microbiology identifies AMS as a distinct set of curriculum capabilities. The evidence you submit for AMS should address: your role in formal stewardship activities (AMS ward rounds, prescribing reviews, PRISM or equivalent programme participation); your contribution to formulary or guideline development; and your involvement in stewardship governance (AMS committee, antimicrobial prescribing programme).
What carries little weight
- A general statement that you participate in AMS activities at your Trust
- Listing AMS as part of your job plan without specific documented activities
- Citing Trust-level antibiotic consumption data without your personal contribution
- Reflections that describe what AMS is rather than what you did
- Generic stewardship teaching without learning objectives or documented outcomes
What carries real weight
- AMS ward round records showing specific prescribing interventions and their outcomes
- IV-to-oral switch data from EPMA or ward round notes, attributed to you
- A formulary or prescribing guideline you authored or substantially contributed to
- An audit of antibiotic prescribing with your name as lead or co-author
- AMS committee minutes confirming your advisory contributions over time
AMS ward rounds as portfolio evidence
The AMS ward round is the most tractable form of stewardship evidence because it generates a contemporaneous record. When you conduct a prescribing review on a ward - checking whether empirical antibiotics can be de-escalated following culture results, whether IV antibiotics can be switched to oral, whether treatment duration can be shortened against clinical guidelines - those decisions are documented in the patient's electronic prescribing and medicines administration (EPMA) record and in the ward notes. An extract from EPMA showing the prescribing interventions you made during AMS rounds, combined with a brief log of your attendance frequency and the wards covered, is credible, verifiable evidence.
The most meaningful AMS ward round entries are those where the intervention was clinically significant: de-escalation from a carbapenem following susceptibility data showing sensitivity to a narrower agent; stopping prophylactic antibiotics in a surgical patient where the indication had passed; switching an aminoglycoside-based regimen to monotherapy after a therapeutic drug monitoring result. Cases like these demonstrate both your microbiological knowledge and your clinical communication skills. Document them with a brief reflection covering the clinical context, the prescribing rationale before your intervention, and what your advice changed. The audit and closing the loop guide covers how to turn recurring AMS data into formal audit evidence.
Guideline and formulary contributions
If you have led or substantially contributed to the development or revision of an antimicrobial prescribing guideline at your Trust or for a professional body, this is high-value evidence that addresses both the AMS curriculum capability and the leadership and management evidence domain. Include the guideline itself (or the relevant sections), an explanation of your role in its development, the evidence base you drew on, and a brief reflection on how its implementation has changed prescribing behaviour where you can demonstrate that. A guideline that was approved and sits unused is much weaker evidence than one that demonstrably changed practice.
Quality markers for microbiology applications
Quality markers in medical microbiology evidence serve the same purpose as in other pathology specialties: they provide independent, externally verifiable confirmation of your diagnostic and practice standards. The most credible quality markers are those that do not originate with you personally but come from laboratory systems, external assessors, or formal audit processes.
The four most important quality marker categories for a medical microbiology application are:
Laboratory turnaround time data: The time from specimen receipt to authorised result, particularly for urgent specimens such as blood cultures, CSF, and urgent wound swabs, is a measurable quality indicator tied to patient safety. Your LIS can generate a turnaround time profile for the specimens you have authorised. Present this as a table against the relevant PHE or Trust benchmark, with a brief reflection on any periods of deviation and their cause. The UK Health Security Agency (formerly Public Health England) publishes reference values for blood culture turnaround times against which you can benchmark your personal data.
EQA performance: As noted in the laboratory diagnostics section, UK NEQAS performance is the most objective external quality marker available to a microbiologist. Your EQA results - showing your identification accuracy and susceptibility interpretation against the consensus answers - should be included as a standalone quality section in your portfolio, not embedded in the main body of the evidence file.
AMS metrics: If your Trust's pharmacy or AMS programme tracks prescribing quality indicators - days of therapy (DOT) per 1,000 bed days, defined daily doses (DDD), or IV-to-oral switch rates - and your ward round activity can be tied to these data, include the relevant metrics with a clear explanation of your contribution. The specific connection between your AMS activity and any measurable change in prescribing behaviour is more persuasive than aggregate Trust-level data.
Audit outputs: Antimicrobial prescribing audits, HCAI surveillance audits, and laboratory quality audits where you are named as lead or co-investigator are formal quality evidence items. The audit evidence guide sets out how to present these to demonstrate that the audit cycle was genuinely completed, not just initiated. Research outputs and formal publications, where relevant, are covered in the research and publications evidence guide.
The ten-year evidence window
Pathology specialties, including medical microbiology, generally operate a ten-year evidence window rather than the five-year window that applies in most clinical specialties. This means that evidence from the past decade can be included and carries full weight. It is a meaningful difference for microbiologists who may have taken on a primarily laboratory management or advisory role in recent years and whose hands-on laboratory practice is now less intensive than it was earlier in their career.
The ten-year window allows you to draw on a longer period of accumulated practice, but it does not mean that recent evidence is less important. The bulk of your evidence should still come from the final three to four years of your log period, because that is what gives assessors confidence about your current standard of practice. Evidence from seven or eight years ago addresses breadth and experience; evidence from the past three years addresses currency. Both are needed. The recent evidence and the five-year rule article covers the general principle in detail - the same logic applies to the ten-year window, just stretched over a longer horizon.
If a curriculum capability - for example, certain specialised culture techniques or an area of molecular diagnostics that your Trust no longer performs - is primarily evidenced by work done more than five years ago, include it but contextualise it explicitly. A brief explanatory sentence noting that the technique has been superseded in your laboratory's scope, or that your Trust now refers this work to a specialist centre, is more credible than leaving assessors to wonder why there is no recent evidence in that area. Honesty about scope changes is not a weakness if it is explained.
Always confirm the current currency-of-evidence rules in the live version of the GMC SSG for Medical Microbiology before building your evidence strategy. The SSG can be updated, and the evidence window rules are defined there, not in this article. If there is any ambiguity between the ten-year norm for pathology specialties and a shorter requirement stated in a specific section of the SSG, the SSG takes precedence.
Overseas doctors: the additional evidential challenge
Medical microbiology applicants who have trained or practised primarily outside the UK face a specific set of evidential challenges that go beyond the general difficulty of applying from overseas. The clinical advisory work in UK NHS microbiology happens within a specific regulatory and cultural framework: the relationship between the laboratory and clinical teams, the structure of antimicrobial stewardship programmes, the HCAI surveillance reporting requirements, and the role of the DIPC are all features of the NHS system that may not have direct equivalents in other healthcare systems.
Evidence of advisory work from a healthcare system with very different antimicrobial resistance patterns, different prescribing norms, or a different relationship between clinical teams and the laboratory will need to be explicitly contextualised. An AMS ward round at a hospital with very low antibiotic use and different empirical prescribing guidelines demonstrates stewardship knowledge but may not map directly to the NHS stewardship framework that RCPath assessors understand. A mapping document explaining how your overseas practice aligns with the GMC SSG requirements is worth investing time in.
The honest picture for doctors applying directly from overseas is that the advisory and stewardship pillars are particularly difficult to evidence without UK NHS experience. Laboratory diagnostics evidence from overseas institutions is easier to verify - EQA participation exists internationally, LIS data is portable, and diagnostic accuracy is less system-dependent. But the IPC and AMS pillars are deeply embedded in the NHS governance and reporting structure, and assessors will need to see evidence that you understand how to work within that structure, not just that you understand IPC and AMS principles in the abstract. A period of UK NHS practice, even as a locum consultant or in a trust grade role, before opening your application window is strongly advisable. The article on translating overseas evidence for the Portfolio Pathway covers the broader principles.
Packaging your submission
A medical microbiology Portfolio Pathway application that contains all the evidence described above will be a substantial document. How you organise it is as important as what it contains, because assessors are reviewing multiple applications and will form an impression of your portfolio within the first few minutes of opening it. A clearly indexed submission, with each pillar given its own section and the evidence within each section clearly mapped to the relevant curriculum capability, makes it easy for an assessor to reach a positive conclusion. An unstructured submission with evidence scattered across the file creates work for the assessor and increases the risk that something is missed.
A cover sheet for the submission as a whole, listing the sections, the log period covered, and your current post and grade, allows an assessor to navigate directly to the evidence they need. The curriculum mapping within each section - explicitly citing the relevant capability number from the SSG against each piece of evidence - is the difference between evidence that is easy to evaluate and evidence that leaves the assessor inferring where things fit.
Multi-source feedback (MSF) in medical microbiology should come from colleagues across all four pillars of practice. Raters from laboratory staff (biomedical scientists, laboratory manager) should be combined with raters from clinical colleagues (ward doctors, infectious diseases physicians, pharmacists, IPC nurses) so that the MSF covers both the laboratory role and the advisory and stewardship roles. An MSF set drawn entirely from laboratory staff addresses Pillar 1 but leaves Pillars 2, 3, and 4 without independent verification. The MSF planning article covers how to select raters strategically across your full scope of practice.
Structured reports from referees should include at least one person who can address your clinical advisory role directly. A laboratory director who can confirm your authorisation standards and EQA performance is a strong Pillar 1 referee; a lead infectious diseases clinician or a pharmacy-based AMS lead who can confirm your advisory and stewardship contributions is equally valuable for Pillars 2 and 4. The structured reports and referees guide covers how to choose and brief referees effectively.
Start the advisory log now, not when you plan to apply
Set up a simple spreadsheet or document for your advisory referral log today. Each entry takes two to three minutes to write up at the end of a busy advisory day. A log maintained over two years of practice is far more persuasive than the same number of entries compiled in three months before submission.
Request your LIS authorisation summary
Contact your laboratory manager and ask what the system can generate for a named personal authorisation summary. Establish the report now so you know what data will be available when you build your portfolio, and whether you need to supplement it with a signed confirmatory letter from the lab manager.
Enrol in EQA under your own identifier if not already enrolled
Check with your laboratory quality lead whether you are enrolled in UK NEQAS schemes individually rather than under the laboratory registration only. If not, arrange individual enrolment through the quality lead. EQA results that identify you personally are the most credible quality evidence you can generate.
Map your IPC contributions against the curriculum capabilities
Review the IPC capabilities listed in the GMC SSG and honestly assess which are well-evidenced, which are thin, and which are absent from your current practice. For the thin or absent ones, decide whether you can build evidence before you apply or whether you need to explain the gap contextually. Do not leave IPC to chance.
Build your AMS evidence file explicitly
Start a dedicated AMS evidence folder: AMS ward round records, EPMA intervention data, any guideline contributions, prescribing audit outputs, committee membership records. The fact that AMS is embedded in your clinical practice does not mean it is automatically captured in your evidence. It needs its own dedicated file.
Review the application mechanics and costs
Before opening the GMC Online window, review the GMC Online application walkthrough and the Portfolio Pathway costs guide. The microbiology evidence preparation described above is time-consuming; allow six to twelve months to assemble it before starting the formal application clock.
All 18 specialisms
This article is part of the Medical Microbiology evidence cluster. The parent overview and all other specialism guides are linked below. Medical Microbiology's sister pathology specialty, Histopathology, also has a dedicated deep-dive covering its evidence documentation challenges.
Read this article alongside the microbiology overview and the general evidence guides it cross-references. The next-sequence below follows the most logical reading path for a Medical Microbiology applicant building their portfolio.